Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 19 for:    Ganaxolone

RAndomized Therapy In Status Epilepticus (RAISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04391569
Recruitment Status : Not yet recruiting
First Posted : May 18, 2020
Last Update Posted : October 20, 2020
Sponsor:
Information provided by (Responsible Party):
Marinus Pharmaceuticals

Brief Summary:
This study will evaluate the effectiveness and safety of an investigational product, IV ganaxolone, to treat subjects with status epilepticus.

Condition or disease Intervention/treatment Phase
Status Epilepticus Convulsive Status EPILEPTICUS Non-Convulsive Status Epilepticus Epilepsy Drug: Ganaxolone Drug: Placebo Phase 3

Detailed Description:

This is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of IV ganaxolone in status epilepticus. Investigational product will be added to standard of care before IV anesthetic during the treatment of SE. Subjects will be screened for inclusion/exclusion criteria prior to receiving investigational product by continuous IV infusion. Subjects will be followed for approximately 4 weeks.

Subjects who are known to be at risk for SE may be consented or assented prior to an SE event.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus
Estimated Study Start Date : October 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : March 2022


Arm Intervention/treatment
Placebo Comparator: IV Placebo
Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
Drug: Placebo
Double-blind study that will randomize subjects to ganaxolone or placebo in 1:1 ratio.

Experimental: IV ganaxolone active
Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
Drug: Ganaxolone
Double-blind study that will randomize subjects to ganaxolone or placebo in 1:1 ratio.




Primary Outcome Measures :
  1. SE Cessation [ Time Frame: 30 minutes ]
    Proportion of participants with status epilepticus cessation within 30 minutes of IP initiation without medications for the acute treatment of status epilepticus. SE cessation is determined by clinical and EEG findings.

  2. Progression to IV anesthesia [ Time Frame: 36 hours ]
    Proportion of participants with no progression to IV anesthesia for 36 hours following IP initiation


Secondary Outcome Measures :
  1. Progression to IV anesthesia [ Time Frame: 72 hours ]
    No progression to IV anesthesia for 72 hours following IP initiation

  2. SE Cessation [ Time Frame: 48 hours ]
    Time to SE cessation following IP initiation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical and/or electrographic seizures

Exclusion Criteria:

  • life expectancy of less than 24 hours
  • anoxic brain injury for an uncontrolled metabolic condition as primary cause of SE
  • treatment of current SE episode with IV anesthetics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04391569


Contacts
Layout table for location contacts
Contact: Maciej Gasior, MD, PhD 484-639-4875 mgasior@marinuspharma.com
Contact: Heather Van Heusen, M Ed 484-802-2470 hvanheusen@marinuspharma.com

Sponsors and Collaborators
Marinus Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Maciej Gasior, MD, PhD Marinus Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Marinus Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04391569    
Other Study ID Numbers: 1042-SE-3003
First Posted: May 18, 2020    Key Record Dates
Last Update Posted: October 20, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Marinus Pharmaceuticals:
seizure
Additional relevant MeSH terms:
Layout table for MeSH terms
Status Epilepticus
Nervous System Diseases
Seizures
Neurologic Manifestations